Walk down the supplement aisle at a Walmart in 2026 and somewhere between the melatonin gummies and the fish oil you will find a small navy box that makes an unusual promise. It is a probiotic. It is not, however, for your stomach. It is for your lungs. The brand is resbiotic, and that box - resB Lung Support - is the company's argument made physical: that the bacteria in your gut have been talking to the rest of your body the whole time, and almost nobody bothered to listen.
resbiotic today is a roughly sixteen-person microbiome company with products in two national retailers, a B2B ingredients arm, and about $20.6 million in the bank across six rounds. It sells supplements named like lab samples - resB, resG, resM, resW, resO - each letter pointed at a different organ system. The connective idea is something the company calls the Gut-X Axis. The "X" is deliberately unfinished. It is a placeholder for whatever the gut turns out to be connected to next.
The Problem They SawThe aisle had a credibility problem
The supplement industry has a reputation, and it is not a flattering one. Bold claims, thin evidence, a regulatory framework that treats "structure/function" language as a loophole rather than a leash. For most shoppers the choice is between products that are cheap and unproven or expensive and unproven. Trust is the scarce ingredient, and almost no one was selling it.
resbiotic's founder had spent years on the other side of that divide. Dr. C. Vivek Lal is a double board-certified physician who ran NIH-funded microbiome research at the University of Alabama at Birmingham's Pulmonary Microbiome Lab. His world ran on randomized trials and peer review. The supplement world ran on testimonials. The gap between those two worlds was the opening.
The Founders' BetA pulmonologist walks into the gut
In 2020 Lal founded the ResBiotech Innovation Institute and, out of it, resbiotic. The bet was specific and slightly contrarian. While the rest of the category piled into bloating, regularity, and the gut-brain axis, Lal pointed his first product at the lungs - the system he actually knew. The gut-lung axis was real in the literature and nearly absent from the shelf. That was the whole opportunity.
He did not arrive alone. The early team read like a hospital org chart wearing a startup hoodie: a chief medical officer, a chief operating officer with a Harvard engineering and MBA pedigree, a probiotics-veteran strategy lead, and a scientific advisory board of microbiome researchers. The first money - a $3 million seed from Timberline Holdings - landed in April 2021. The point of all that credentialing was not vanity. It was the product.
A company that names its founder's PhD before its flavor profile is telling you what it competes on.
The ProductProbiotics with a destination
The flagship, resB Lung Support, is marketed as the first clinically tested probiotic built for the gut-lung axis and the number-one physician-recommended lung-health probiotic. The thesis is that the right gut bacteria can dial down the kind of inflammation that shows up in airways - a medical-food approach the founding lab originally framed as reducing neutrophilic inflammation in people with chronic respiratory conditions.
From there the line fans out across the body. resM is a GLP-1 postbiotic aimed at metabolism, cravings, and blood sugar - the company's nod to the weight-management moment. resG is a beet-based prebiotic for clean energy. resW targets perimenopause. resO covers bone and joint. There is an at-home gut test to personalize the whole thing. Five letters, five systems, one underlying claim: fix the gut and the rest follows.
How a lab idea became a shelf
The ProofWhere the money and the shelves agree
Claims are cheap; distribution is not. By late 2025 resbiotic had products in Walmart stores nationwide and on GNC shelves, a direct-to-consumer business running on Shopify with subscriptions, and a fresh $8 million Series A inside a $14.5 million raise. Investors Sororibus Capital and Biostack Ventures were not buying the lung probiotic so much as the platform underneath it - and the B2B ingredients business that lets resbiotic sell its microbiome formulations to other brands.
The audience splits three ways, and the company seems comfortable with all three. There are the retail shoppers, who meet resbiotic cold on a shelf and judge it in four seconds. There are the healthcare providers, who the brand courts hard - the "physician-recommended" framing is aimed squarely at clinicians who would never recommend a typical supplement. And there are the brands and manufacturers buying the B2B ingredients, who care about formulations and stability data, not packaging. The products are HSA and FSA eligible, which is a small detail that says something larger: resbiotic wants to be filed under healthcare, not wellness.
It has also leaned on the modern proof-of-credibility machine - third-party stability testing, healthcare-expert endorsements, and collaborations with figures like Dave Asprey and Dr. Kunal Sood. Borrowed authority is a double-edged sword in this category, and resbiotic knows it; the influencer co-signs sit alongside, not instead of, the lab work. The company's own culture reflects the same instinct. It describes itself as gut-obsessed, which is a marketing line, but the org chart - chief medical officer, scientific advisory board, a founder who still reads like a principal investigator - suggests the obsession is genuine.
The funding climb
The MissionRestore the gut, and beyond
The company's tagline - "Restore the gut & beyond" - is doing more work than a tagline usually does. The "beyond" is the entire wager. resbiotic calls itself gut-obsessed, but the obsession points outward: respiratory, metabolic, hormonal, skeletal. The mission is to treat the microbiome less like a digestive curiosity and more like whole-body infrastructure, and to do it with the one thing the category keeps skipping - actual clinical validation.
It is an easy mission to say and a hard one to keep. Every new "X" the company adds is another claim it has to stand behind, another organ system that has to cooperate with the science. That is the discipline the founder's credentials are meant to enforce. Whether it holds at retail scale is the open question - and, conveniently, the reason the platform exists.
Why It Matters TomorrowThe microbiome is still mostly unread
Here is the thing the skeptics and the believers both quietly agree on: we are early. The science connecting the gut to distant organs is real but young, and most of it has never been packaged into something you can buy at a Walmart. resbiotic is one of the few companies trying to translate that research into shelf-ready products without throwing out the rigor on the way. If the gut-lung axis pans out, the gut-X anything becomes a roadmap.
Back in that Walmart aisle, the navy box is still making its quiet, slightly improbable claim. A probiotic for your lungs. Five years ago that sentence belonged in a research abstract. Now it belongs on an end-cap, between the melatonin and the fish oil, waiting for a skeptical shopper to pick it up and read the science on the back. resbiotic's entire bet is that they will.